Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility

This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.

Detalles Bibliográficos
Autores principales: Brenner Thomsen, Caroline, Dandanell Juul, Amanda, Lefèvre, Anna Cecilie, Glismand Truelsen, Christina, Dizdarevic, Edina, Ryssel, Heidi, Mathilde Kjær, Ina, Lycke Wind, Karen, Callesen, Louise Bach, Faaborg Larsen, Louise, Støchkel Frank, Malene, Fredslund Andersen, Rikke, Garm Spindler, Karen‐Lise, Jakobsen, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543969/
https://www.ncbi.nlm.nih.gov/pubmed/35302663
http://dx.doi.org/10.1002/cncr.34168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543969/
https://www.ncbi.nlm.nih.gov/pubmed/35302663
http://dx.doi.org/10.1002/cncr.34168

Ejemplares similares